Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05769478 · ClinicalTrials.gov registry record · Phase 1
Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA
A Phase 1 study of Botulism and Iatrogenic Botulism, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT05769478 is a Phase 1 study of Botulism and Iatrogenic Botulism that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 21 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05769478, a Phase 1 study of Botulism and Iatrogenic Botulism, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
if amifampridine can improve neuromuscular transmission in muscles previously injected with OnabotulinumtoxinA (BTX-A)
Conditions Studied
Interventions
- DRUG Amifampridine
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2023-09-15 |
| Est. Completion | 2024-10-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05769478
The ClinicalTrials.gov registry entry for NCT05769478 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Botulism appearing as the primary indexed condition, and to 1 intervention - of which Amifampridine is the first listed.
NCT05769478 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05769478 about?
NCT05769478 is a clinical study titled "Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA". if amifampridine can improve neuromuscular transmission in muscles previously injected with OnabotulinumtoxinA (BTX-A)
What is the current status of trial NCT05769478?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2023-09-15. Estimated completion is 2024-10-29.
What conditions does trial NCT05769478 study?
This clinical trial studies the following conditions: Botulism, Iatrogenic Botulism.
What interventions are being tested in trial NCT05769478?
The interventions under investigation include: Amifampridine (DRUG).
Who is sponsoring clinical trial NCT05769478?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05769478 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Botulism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.